LENZ Therapeutics, Inc. Q4 FY2024 earnings call

Regulatory: Constructive process with FDA, mid-cycle review completed in January 2024 with no significant issues, FDA inspections on clinical trial sites underway, confident in NDA review progress, expecting on-time approval in August 2025 and commercial launch in Q4 2025. ### Manufacturing Readiness: Initiated manufacturing of potential commercial products in February, working on building pre-approval commercial product and sample inventory. ### Medical Affairs: All-optometrists medical science liaison team engaging with ECPs on medical education, EYEAMSELECTIVE unbranded campaign driving ECP awareness. ### Intellectual Property: Strengthened patent estate with 7 granted US patents and 10 pending, aiming for extended protection, well-protected for longevity. ### Pre-launch Commercial Planning: Sales force hiring in final stage, hired regional directors and district managers, upcoming commercial day on April 15th to elaborate on commercial strategy

No traditional product segment breakdown provided. Overall, the company ended 2024 with over $209 million in cash. Fourth quarter operating expenses were approximately $15.2 million, with R&D expenses at $5.9 million, and net loss per share at $0.46 per share.

Anticipate on-time approval of LNZ100's NDA in August 2025 with commercial launch in Q4 2025. ### Ended 2024 with over $209 million in cash, indicating financial strength. ### Confident in progress towards PDUFA date of August 8th, 2025

FDA inspection of clinical trial sites underway, but company confident in NDA review progress. ### Potential differences between forward-looking statements and actual results due to various factors and risks discussed in SEC filings

Q: Yigal Nochomovitz asked about filtering ECPs for sales force, awareness campaign, and launch timing.

A: Shawn Olsson and Eef Schimmelpennink responded, discussing focus on high prescribers of presbyopia scripts, growth in unbranded awareness, and launch timing factors like manufacturing and labeling.

Q: Madhu Yennawar asked about sampling duration and regulatory process.

A: Eef Schimmelpennink responded, stating sampling is well-suited due to clinical data and FDA interactions being productive with mid-cycle review benign and inspections ongoing.

Q: Joe Catanzaro asked about competitive landscape and Phase 4 studies.

A: Shawn Olsson and Eef Schimmelpennink responded, emphasizing LNZ100's unique pupil-selective MOA and plans for Phase 4 studies as needed.

Q: Stacy Ku asked about awareness campaign, consumer messaging, and sales force background.

A: Shawn Olsson and Eef Schimmelpennink responded, discussing progress in educational campaign, consumer messaging focusing on realistic expectations, and sales force hiring with strong candidate pool.

Q: Jason Gerberry asked about sampling, e-pharmacies, and patient comorbidities.

A: Shawn Olsson and Eef Schimmelpennink responded, clarifying sampling and e-pharmacy processes are separate, and early adopters include contact lens wearers and those with refractive surgery.

Q: Lachlan Hanbury-Brown asked about sales rep access and macroeconomic impact.

A: Shawn Olsson and Eef Schimmelpennink responded, stating sales rep access to optometrists is not challenging, and no significant macroeconomic impact expected on presbyopia market.

Q: Denis Reznik asked about consumer segments and EU commercialization.

A: Shawn Olsson and Eef Schimmelpennink responded, discussing accessibility of consumer segments and plans to up-license ex-U.S. territories, with focus on U.S. commercialization first.

Q: Matthew Caufield asked about prescription resistance based on Vuity experience.

A: Shawn Olsson responded, stating high excitement and willingness to prescribe LNZ100 among ECPs due to its non-pilocarpine basis and better efficacy profile